Therapy with JAK Inhibitors or bDMARDs and the Risk of Cardiovascular Events in the Dutch Rheumatoid Arthritis Population
Rheumatology (Oxford) 2023 doi 10.1093/rheumatology/kead531 Epub ahead of print
Popa, et al. compared the incidence of CV events between JAKi and bDMARD therapies in a large RA population, and found no significant difference in CV risk between the treatment groups. They also compared CV risk between baricitinib-treated and tofacitinib-treated patients and found no significant difference.
Differential Properties of Janus Kinase Inhibitors in the Treatment of Immune-mediated Inflammatory Diseases
Rheumatology (Oxford) 2023 doi 10.1093/rheumatology/kead448 Epub ahead of print
JAKis differ in structure, which affects their inhibitory concentration for different JAKs.
This review by Taylor, et al. compares the pharmacological profiles of JAKis, including abrocitinib, baricitinib, filgotinib, peficitinib, tofacitinib, and upadacitinib.
Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis
Pharmacology 2023 doi 10.1159/000527186 Epub ahead of print
The results of a Bayesian network meta-analysis by Lee and Song showed that JAK inhibitors were more likely to achieve remission and LDA in DMARD-naive RA patients than MTX. However, there were no significant differences in remission rates nor LDA rates between the JAK inhibitors investigated.
One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib
Adv Ther. 2023 doi 10.1007/s12325-023-02619-6 Epub ahead of print
This study by Bergman, et al. showed that RA patients are significantly more likely to adhere to upadacitinib within the first 12 months of prescription versus adalimumab, baricitinib, and tofacitinib. There was also a significantly lower risk of discontinuation for upadacitinib versus the other treatment prescriptions.
J. Clin. Med. 2023;12(13):4527 doi 10.3390/jcm12134527
This review by Taylor, et al. reviews the long-term safety and efficacy data for baricitinib. Results from several studies showed that baricitinib has greater efficacy and survival compared to TNF inhibitors, and that the rate of CDAI <10 for baricitinib-treated RA patients increased over the course of seven years. Data also showed that remission rates were higher in real-world evidence than in RCTs.
Baricitinib in Juvenile Idiopathic Arthritis: An International, Phase 3, Randomised, Double-blind, Placebo-controlled, Withdrawal, Efficacy, and Safety Trial
Lancet. 2023 S0140-6736(23)00921-2 doi 10.1016/S0140-6736(23)00921-2 Epub ahead of print
Phase 3 trial of baricitinib demonstrates efficacy with acceptable safety profile in polyarticular and extended oligoarticular juvenile idiopathic arthritis, juvenile psoriatic arthritis and enthesitis-related arthritis.
Comparative Effectiveness of First-Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set
ACR Open Rheumatol. 2023 doi 10.1002/acr2.11577 Epub ahead of print.
Cicirello, et al. present results showing that baricitinib is comparable in treatment persistence with TNF inhibitors. However, treatment persistence up to 24 months was significantly longer for baricitinib, but the effect size of one month is not clinically meaningful.
Ann Rheum Dis. 2023;2023-224049 doi: 10.1136/ard-2023-224049 Epub ahead of print
The objective of this study was to estimate the association of JAKi with the incidence of malignancy, compared with placebo, TNFi and MTX.
Baricitinib Improves Bone Properties and Biomechanics in Patients with Rheumatoid Arthritis – Results of the Prospective Interventional BARE BONE Trial
Arthritis Rheumatol. 2023 doi 10.1002/art.42617 Epub ahead of print
The results from Simon, et al. show that baricitinib treatment correlates with improvements in bone stiffness. Further improvements were also observed at the end of Week 52, with an increase in estimated failure load and no measurable progression in bone erosion being reported.
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Adv Ther. 2023:1–17 doi: 10.1007/s12325-023-02445-w Epub ahead of print
Analysis of pooled data from the baricitinib clinical development programmes finds a low incidence rate of MACE, myocardial infarction, lung cancer, VTE, and overall mortality in patients <65 years without risk factors.